Goldin Ilja, Medinger Michael, Passweg Jakob, Halbeisen Delia
Division of Internal Medicine, Department of Medicine, University Hospital Basel and University of Basel, Basel, Switzerland.
Division of Hematology, Department of Medicine, University Hospital Basel and University of Basel, Basel, Switzerland.
Case Rep Oncol. 2024 Oct 1;17(1):1103-1108. doi: 10.1159/000541328. eCollection 2024 Jan-Dec.
All-trans retinoic acid (ATRA) in combination with arsenic trioxide (ATO) is standard therapy for low-to-intermediate risk acute promyelocytic leukemia (APL). Isotretinoin, an agent used for acne vulgaris, is similar in its chemical structure and effects to ATRA, and single-case studies report a probable effectiveness in APL.
In this case, a patient with newly diagnosed APL was treated with isotretinoin/ATO instead of ATRA/ATO for nearly 4 weeks due to a prescription error and anyway reached a stable complete remission as if treated with ATRA/ATO.
Treatment of APL with isotretinoin instead of ATRA could possibly be effective.
全反式维甲酸(ATRA)联合三氧化二砷(ATO)是低至中危急性早幼粒细胞白血病(APL)的标准治疗方法。异维甲酸是一种用于治疗寻常痤疮的药物,其化学结构和作用与ATRA相似,单病例研究报告其在APL中可能有效。
在此病例中,一名新诊断的APL患者因处方错误接受了近4周的异维甲酸/ATO治疗而非ATRA/ATO治疗,无论如何,该患者达到了稳定的完全缓解,就好像接受了ATRA/ATO治疗一样。
用异维甲酸而非ATRA治疗APL可能有效。